By Sabela Ojea
Renovaro said it named Nathen Fuentes as its permanent finance chief to succeed interim CFO Simon Tarsh.
The cancer diagnostics and therapeutics company on Tuesday said Fuentes, who previously served as CFO of Telomir Pharmaceuticals, has experience leading acquisition and organic growth initiatives.
The Los Angeles-based company on Monday agreed to acquire Predictive Oncology, which owns a database of 150,000 frozen and live tumor samples and more than 20 years of drug-response data.
In a letter to shareholders, Chief Executive David Weinstein also said Nasdaq notified the company it is now in good standing.
He added that the company has now "taken critical steps in building a point of care cancer detection and vaccine company and will continue to update you regularly on our progress."
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
January 07, 2025 09:49 ET (14:49 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。